C
Carna Biosciences
Kinase inhibitor drug discovery and development services
About Carna Biosciences
Carna Biosciences is a clinical-stage biopharmaceutical company that operates through two main business segments: Drug Discovery Support and Drug Discovery and Development. Founded in April 2003 as a spin-off from the research division of Nippon Organon K.K. in Kobe, Japan, the company focuses on developing therapies for serious unmet medical needs, particularly in oncology and autoimmune diseases. The President and CEO, Kohichiro Yoshino, founded the company after heading the Osaka Research Center for Nippon Organon. The company went public in March 2008, listing on the JASDAQ exchange.
The Drug Discovery Support business provides a stable income by offering a wide range of products and services to pharmaceutical companies and academic researchers worldwide to support their kinase inhibitor research. Offerings include one of the world's largest selections of kinase proteins, assay kits, and profiling and screening services using their proprietary QuickScout™ technology. This segment leverages the company's core technological strengths in kinase production, profiling, and assay development.
The Drug Discovery and Development business uses the funds generated from the support segment to advance its own pipeline of small molecule kinase inhibitors. The business model involves advancing drug candidates through preclinical and clinical stages and then out-licensing the intellectual property rights to pharmaceutical partners for further development and commercialization. This generates revenue through upfront payments, developmental and commercial milestones, and sales royalties. The company's pipeline includes candidates for cancer and inflammatory and immune disorders, such as AS-0871, which is in Phase 1 clinical trials. Carna Biosciences has established collaborations with major pharmaceutical companies, including Janssen Biotech and Gilead Sciences.
Source: Dealroom company dataNews
Open roles
Carna Biosciences in the Kobe ecosystem
The Carna Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed17 investors entered at this stage
Mizuho Capital
JAFCO
Whiz Partners
Bio-sight Capital
Mitsubishi UFJ Capital
SBI Investment
Mitsubishi UFJ Financial GroupAG Capital
- TFTokyo Finance
Tokyo Capital- MCMU Hands-on Capital
Mizuho Securities
Japan Asia Investment
Senshu Ikeda Capital
Minato Capital
Mitsui Sumitomo Insurance Venture Capital- SISummit Pharmaceuticals International
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Carna Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Carna Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.